| scholarly article | Q13442814 |
| P356 | DOI | 10.1002/EJHF.1298 |
| P698 | PubMed publication ID | 30225956 |
| P50 | author | Renata De Maria | Q72700965 |
| Margaret M Redfield | Q98243295 | ||
| P2093 | author name string | Gianfranco Parati | |
| Giovanni Cioffi | |||
| Antonello Gavazzi | |||
| Attilio Iacovoni | |||
| Michele Senni | |||
| Mauro Gori | |||
| Paola Ferrari | |||
| Aurelia Grosu | |||
| Alice Calabrese | |||
| Alessandra Fontana | |||
| Paolo Canova | |||
| P2860 | cites work | Resource Effective Strategies to Prevent and Treat Cardiovascular Disease | Q26768304 |
| A Randomized Trial of Intensive versus Standard Blood-Pressure Control | Q27231406 | ||
| 2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines | Q29620107 | ||
| New strategies for heart failure with preserved ejection fraction: the importance of targeted therapies for heart failure phenotypes | Q34375466 | ||
| Prognosis of all-cause heart failure and borderline left ventricular systolic dysfunction: 5 year mortality follow-up of the Echocardiographic Heart of England Screening Study (ECHOES). | Q34622891 | ||
| 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC). Developed with the special contrib | Q34677347 | ||
| Burden of systolic and diastolic ventricular dysfunction in the community: appreciating the scope of the heart failure epidemic | Q35040738 | ||
| Progression of left ventricular diastolic dysfunction and risk of heart failure | Q35719757 | ||
| Left atrial size: physiologic determinants and clinical applications | Q36509741 | ||
| The natural history of preclinical diastolic dysfunction: a population-based study | Q36564049 | ||
| Influence of ejection fraction on outcomes and efficacy of spironolactone in patients with heart failure with preserved ejection fraction | Q36573602 | ||
| Natriuretic Peptide and High-Sensitivity Troponin for Cardiovascular Risk Prediction in Diabetes: The Atherosclerosis Risk in Communities (ARIC) Study. | Q36820589 | ||
| Prognostic Importance of Changes in Cardiac Structure and Function in Heart Failure With Preserved Ejection Fraction and the Impact of Spironolactone. | Q37075193 | ||
| Comparison of ventricular structure and function in Chinese patients with heart failure and ejection fractions >55% versus 40% to 55% versus <40%. | Q37082859 | ||
| The prognostic value of N-terminal pro-B-type natriuretic peptide for death and cardiovascular events in healthy normal and stage A/B heart failure subjects | Q37163361 | ||
| Prevalence and prognosis of asymptomatic left ventricular diastolic dysfunction in ambulatory patients with coronary heart disease | Q37423864 | ||
| The development of heart failure in patients with diabetes mellitus and pre-clinical diastolic dysfunction a population-based study. | Q37425444 | ||
| Pre-clinical diastolic dysfunction | Q37603551 | ||
| Recommendations for cardiac chamber quantification by echocardiography in adults: an update from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. | Q38364873 | ||
| Importance of Clinical Worsening of Heart Failure Treated in the Outpatient Setting: Evidence From the Prospective Comparison of ARNI With ACEI to Determine Impact on Global Mortality and Morbidity in Heart Failure Trial (PARADIGM-HF). | Q38392958 | ||
| Natriuretic peptide-based screening and collaborative care for heart failure: the STOP-HF randomized trial | Q38448978 | ||
| Role of biomarkers in cardiac structure phenotyping in heart failure with preserved ejection fraction: critical appraisal and practical use. | Q38614176 | ||
| Strategy to identify subjects with diabetes mellitus more suitable for selective echocardiographic screening: The DAVID-Berg study. | Q38678451 | ||
| Biomarker Profiles of Acute Heart Failure Patients With a Mid-Range Ejection Fraction | Q38721084 | ||
| Epidemiology and one-year outcomes in patients with chronic heart failure and preserved, mid-range and reduced ejection fraction: an analysis of the ESC Heart Failure Long-Term Registry | Q38848623 | ||
| Prognosis and response to therapy of first inpatient and outpatient heart failure event in a heart failure clinical trial: MADIT-CRT. | Q39243083 | ||
| Effect of enalapril on mortality and the development of heart failure in asymptomatic patients with reduced left ventricular ejection fractions | Q43472007 | ||
| Effects of once-daily angiotensin-converting enzyme inhibition and calcium channel blockade-based antihypertensive treatment regimens on left ventricular hypertrophy and diastolic filling in hypertension: the prospective randomized enalapril study e | Q43733943 | ||
| Natural history of asymptomatic left ventricular systolic dysfunction in the community | Q43884752 | ||
| Predictors and outcomes of heart failure with mid-range ejection fraction | Q46178786 | ||
| Influence of ejection fraction on cardiovascular outcomes in a broad spectrum of heart failure patients | Q46837803 | ||
| Prognostic implications of ejection fraction from linear echocardiographic dimensions: the Strong Heart Study | Q47656775 | ||
| What is the most cost-effective strategy to screen for left ventricular systolic dysfunction: natriuretic peptides, the electrocardiogram, hand-held echocardiography, traditional echocardiography, or their combination? | Q48708508 | ||
| Recommendations for the Evaluation of Left Ventricular Diastolic Function by Echocardiography: An Update from the American Society of Echocardiography and the European Association of Cardiovascular Imaging | Q49036174 | ||
| A comprehensive population-based characterization of heart failure with mid-range ejection fraction | Q49833968 | ||
| Heart failure with mid-range ejection fraction in CHARM: characteristics, outcomes and effect of candesartan across the entire ejection fraction spectrum | Q50068685 | ||
| What have we learned about heart failure with mid-range ejection fraction one year after its introduction? | Q50079611 | ||
| High-Sensitive Cardiac Troponin for Prediction of Clinical Heart Failure: Are We Ready for Prime Time? | Q50722046 | ||
| PONTIAC (NT-proBNP selected prevention of cardiac events in a population of diabetic patients without a history of cardiac disease): a prospective randomized controlled trial. | Q50869983 | ||
| Achievement of goals in U.S. diabetes care, 1999-2010. | Q51045064 | ||
| The middle child in heart failure: heart failure with mid-range ejection fraction (40-50%) | Q85290915 | ||
| Natriuretic peptides and the Framingham risk score for screening of asymptomatic left ventricular systolic dysfunction in high-risk patients in primary care. The DAVID-BERG study | Q87285782 | ||
| Heart failure with preserved ejection fraction: a forest of a variety of trees | Q88018579 | ||
| P433 | issue | 11 | |
| P921 | main subject | systole | Q496359 |
| P304 | page(s) | 1540-1548 | |
| P577 | publication date | 2018-09-17 | |
| P1433 | published in | European Journal of Heart Failure | Q5017954 |
| P1476 | title | Is mild asymptomatic left ventricular systolic dysfunction always predictive of adverse events in high-risk populations? Insights from the DAVID-Berg study | |
| P478 | volume | 20 |
Search more.